Departments of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Departments of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Sci Rep. 2020 Jul 7;10(1):11191. doi: 10.1038/s41598-020-68168-y.
Radiation doses to the heart are potentially high in patients undergoing radiotherapy for thymoma or thymic carcinoma because of their origin site and propensity for pericardial invasion. We investigated potential relationships between radiation pneumonitis (RP) and the dosimetric parameters of lung and heart substructures in patients with thymic epithelial tumors. This retrospective study included 70 consecutive patients who received definitive or postoperative radiotherapy at a median dose of 58.3 Gy. Heart substructures were delineated according to a published atlas. The primary end point of ≥ grade 2 RP was observed in 13 patients (19%) despite a low lung dose; median lung V20 (i.e. percentage of the volume receiving at least 20 Gy) was only 16.6%. In a univariate analysis, four lung parameters, heart V35, three pulmonary artery (PA) parameters, two left ventricle parameters, and left atrium V35 were associated with the development of RP. In a multivariate analysis, only PA V35 remained significant (hazard ratio 1.04; 95% CI 1.01-1.07, p = 0.007). PA V35 of the RP versus non-RP groups were 84.2% versus 60.0% (p = 0.003). The moderate dose sparing of PA could be a candidate as a planning constraint for reducing the risk of RP in thoracic radiotherapy.
在接受胸腺瘤或胸腺癌放疗的患者中,由于其起源部位和心包侵犯的倾向,心脏的辐射剂量可能很高。我们研究了放射性肺炎(RP)与胸内上皮性肿瘤患者肺和心脏亚结构剂量学参数之间的潜在关系。这项回顾性研究纳入了 70 例连续接受根治性或术后放疗的患者,中位剂量为 58.3 Gy。根据已发表的图谱对心脏亚结构进行了勾画。尽管肺剂量较低,但仍有 13 例(19%)患者出现≥2 级 RP;中位数肺 V20(即接受至少 20 Gy 剂量的体积百分比)仅为 16.6%。单因素分析中,4 个肺参数、心脏 V35、3 个肺动脉(PA)参数、2 个左心室参数和左心房 V35 与 RP 的发生相关。多因素分析中,仅 PA V35 仍有显著意义(风险比 1.04;95%CI 1.01-1.07,p=0.007)。RP 组和非 RP 组的 PA V35 分别为 84.2%和 60.0%(p=0.003)。PA 的中等剂量保护可能是作为降低胸部放疗中 RP 风险的计划限制的候选因素。